Liraglutide
Receptor agonism at GLP-1 gives liraglutide its dual application in type 2 diabetes and in obesity. Mimicking the natural incretin, it enhances insulin secretion, suppresses appetite and slows gastric emptying, so glycaemic control and weight reduction arise from a single mechanism acting at pancreatic and central sites. Investigation has extended to cardiovascular and neuroprotective effects beyond those established indications. Its elimination half-life of about 13 hours is intermediate between the native hormone, degraded within minutes, and the weekly analogues developed subsequently. The agent is a protein of formula C172H265N43O51 and roughly 3751 g/mol, classified within the alimentary tract and metabolism group.
A GLP-1 receptor agonist used to treat type 2 diabetes and obesity, and studied for cardiovascular and neuroprotective benefits. It mimics the natural GLP-1 hormone to stimulate insulin secretion, suppress appetite, and slow stomach emptying.
Masse moléculaire
3751,0000 g/mol
LogP
-3,40
TPSA
1510,00 Ų
Règle des 5 de Lipinski
Non conforme
Aires thérapeutiques
Classes de médicaments
Mécanisme d'action
GLP-1 receptor agonist enhancing insulin secretion.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
GLP-1 receptor agonist enhancing insulin secretion.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O
InChI
InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1
Molecular Formula
C172H265N43O51
HBD / HBA
54 / 55
Liaisons Rotatives
132
Atomes Lourds
266
No targets recorded
Target interaction data is not yet available for this drug.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A GLP-1 receptor agonist used to treat type 2 diabetes and obesity, and studied for cardiovascular and neuroprotective benefits. It mimics the natural GLP-1 hormone to stimulate insulin secretion, suppress appetite, and slow stomach emptying.
GLP-1 receptor agonist enhancing insulin secretion.
Key pharmacokinetic parameters for Liraglutide: Half-life: 13 hours.
Yes, Liraglutide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4084119. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 16134956. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="liraglutide"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/liraglutide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/liraglutide/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/liraglutide/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="liraglutide"></drugfyi-drug>